Genetic Variants in Pigment Epithelium-Derived Factor Influence Response of Polypoidal Choroidal Vasculopathy to Photodynamic Therapy

被引:21
作者
Nakata, Isao [1 ,2 ]
Yamashiro, Kenji [1 ]
Yamada, Ryo [2 ]
Gotoh, Norimoto [1 ,2 ]
Nakanishi, Hideo [1 ,2 ]
Hayashi, Hisako [1 ,2 ]
Tsujikawa, Akitaka [1 ]
Otani, Atsushi [1 ]
Ooto, Sotaro [1 ]
Tamura, Hiroshi [1 ]
Saito, Masaaki [3 ]
Saito, Kuniharu [3 ]
Iida, Tomohiro [3 ]
Oishi, Akio [4 ]
Kurimoto, Yasuo [4 ]
Matsuda, Fumihiko [2 ]
Yoshimura, Nagahisa [1 ]
机构
[1] Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Inserm,U852, Kyoto, Japan
[3] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan
[4] Gen Hosp, Kobe City Med Ctr, Dept Ophthalmol, Kobe, Hyogo, Japan
基金
日本学术振兴会;
关键词
GROWTH-FACTOR VEGF; MACULAR DEGENERATION; CIGARETTE-SMOKING; VERTEPORFIN; EXPRESSION; OUTCOMES; PEDF; POLYMORPHISMS; RECURRENCE; GENOTYPE;
D O I
10.1016/j.ophtha.2010.12.011
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To investigate whether photodynamic therapy (PDT) outcomes of polypoidal choroidal vasculopathy (PCV) are related to baseline clinical characteristics, smoking history, or genetic factors by analyzing the retreatment-free period after the first PDT. Design: Retrospective cohort study. Participants: The study consisted of 167 patients with PCV who underwent PDT as their first treatment. Methods: We targeted 638 single nucleotide polymorphisms (SNPs) in 42 possible susceptible genes for age-related macular degeneration to evaluate their relation to the effectiveness of PDT for PCV. For this evaluation, we used 2 methods: (1) survival analysis, with the retreatment-free period as the target; and (2) logistic regression test between the need for additional therapy within 3 months after the first PDT and the genotypes, with age, gender, smoking status, and greatest linear dimension (GLD) at baseline as covariates. The contributions of smoking status and GLD at baseline for the retreatment-free period also were evaluated. Contributions of these factors to visual prognosis were evaluated for 1 year after PDT. Main Outcome Measures: Retreatment-free period after the first PDT for PCV. Secondary outcome measures included correlation of the susceptible factor to the retreatment requirement within the 3-month follow-up and the mean visual acuity change. Results: In survival analyses, SERPINF1 rs12603825 showed a significant association with the retreatment-free period after the first PDT; those patients homozygous for the minor allele A of rs12603825 received additional treatment after PDT within significantly shorter times than those with other genotypes (P = 0.0038). There was no significant difference in the retreatment-free period between baseline GLD and smoking status. Retreatment within 3 months was required significantly more in patients with the AA genotype, even after taking into consideration the effect of clinical characteristics (age, gender), baseline PCV lesion size, and smoking status (P = 0.0027). Furthermore, patients with the AA genotype showed significantly worse visual prognosis after PDT (P = 0.013). Conclusions: Pigment epithelium-derived factor (SERPINF1 or PEDF) polymorphisms may influence the initial response to and visual prognosis after PDT for PCV. Our findings may lead to understanding the pathogenesis of PCV and modification of the effects of PDT.
引用
收藏
页码:1408 / 1415
页数:8
相关论文
共 50 条
[1]   Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration [J].
Arias, L ;
Pujol, O ;
Berniell, J ;
Rubio, M ;
Roca, G ;
Castillo, L ;
Acebes, E .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (03) :312-315
[2]  
Arnold J, 2001, AM J OPHTHALMOL, V131, P541
[3]   Haploview: analysis and visualization of LD and haplotype maps [J].
Barrett, JC ;
Fry, B ;
Maller, J ;
Daly, MJ .
BIOINFORMATICS, 2005, 21 (02) :263-265
[4]   Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration [J].
Bhutto, IA ;
McLeod, DS ;
Hasegawa, T ;
Kim, SY ;
Merges, C ;
Tong, P ;
Lutty, GA .
EXPERIMENTAL EYE RESEARCH, 2006, 82 (01) :99-110
[5]   Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration [J].
Bhutto, Imran A. ;
Uno, Koichi ;
Merges, Carol ;
Zhang, Lei ;
McLeod, D. Scott ;
Lutty, Gerard A. .
ARCHIVES OF OPHTHALMOLOGY, 2008, 126 (05) :670-678
[6]  
Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
[7]   Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial [J].
Campochiaro, PA ;
Nguyen, QD ;
Shah, SM ;
Klein, ML ;
Holz, E ;
Frank, RN ;
Saperstein, DA ;
Gupta, A ;
Stout, JT ;
Macko, J ;
DiBartolomeo, R ;
Wei, LL .
HUMAN GENE THERAPY, 2006, 17 (02) :167-176
[8]   Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy - One-year results of a prospective case series [J].
Chan, WM ;
Lam, DSC ;
Lai, TYY ;
Liu, DTL ;
Li, KKW ;
Yao, Y ;
Wong, TH .
OPHTHALMOLOGY, 2004, 111 (08) :1576-1584
[9]   A prospective study of cigarette smoking and risk of age-related macular degeneration in men [J].
Christen, WG ;
Glynn, RJ ;
Manson, JE ;
Ajani, UA ;
Buring, JE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (14) :1147-1151
[10]   Polypoidal choroidal vasculopathy [J].
Ciardella, AP ;
Donsoff, IM ;
Huang, SJ ;
Costa, DL ;
Yannuzzi, LA .
SURVEY OF OPHTHALMOLOGY, 2004, 49 (01) :25-37